content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): April 21, 2006
                                                            --------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                     000-14879                22-2322400
  ----------------------------   ------------------------   ----------------------
  (State or Other Jurisdiction   (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  ---------------------------------------------------------   --------------------
          (Address of Principal Executive Offices)                 (Zip Code)
  
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  
  <PAGE>
  
  
  ITEM 1.01    ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
  
       On  April  21,   2006,   Cytogen   Corporation   ("Cytogen")   and  Savient
  Pharmaceuticals,  Inc.  ("Savient")  announced the  execution of a  distribution
  agreement   granting  Cytogen   exclusive   marketing  rights  for  SOLTAMOX(TM)
  (tamoxifen  citrate)  in the United  States.  SOLTAMOX,  a  cytostatic  estrogen
  receptor  antagonist,  is the first oral liquid hormonal therapy approved in the
  U.S.  It is  indicated  for the  treatment  of  breast  cancer in  adjuvant  and
  metastatic settings and to reduce the risk of breast cancer in women with ductal
  carcinoma in situ (DCIS) or with high risk of breast cancer.
  
       Under the terms of the final  transaction,  Cytogen paid Savient an upfront
  licensing  fee of $2  million  and will pay  additional  contingent  sales-based
  milestone  payments  of up to a total of $4 million  to  Savient  and its wholly
  owned  subsidiary,  Rosemont  Pharmaceuticals  Ltd  ("Rosemont").   Savient  and
  Rosemont will also receive royalties on net sales of SOLTAMOX
  
       Additionally, Cytogen has entered into a supply agreement with Rosemont for
  the  manufacture  and supply of  SOLTAMOX.  Cytogen  expects to launch  SOLTAMOX
  during the third quarter of 2006.
  
       Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
  copy of the related press release of Cytogen and Savient,  dated April 24, 2006.
  A copy of the  Exclusive  Distribution  Agreement  and the  Manufacture & Supply
  Agreement will be filed as exhibits to Cytogen's  upcoming  quarterly  Report on
  Form 10-Q for the quarter ended March 31, 2006.
  
  ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.      Description
        -----------      -----------
  
           99.1          Press Release of Cytogen and Savient dated April 24, 2006
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By:/s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   April 26, 2006
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
        Exhibit No.      Description
        -----------      -----------
  
            99.1         Press Release of Cytogen and Savient dated April 24, 2006
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_savient042606.txt", "description": "FORM 8-K SAVIENT TRANSACTION", "secsgml_size_bytes": 4960}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "06780419"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): April 21, 2006
                                                            --------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                     000-14879                22-2322400
  ----------------------------   ------------------------   ----------------------
  (State or Other Jurisdiction   (Commission File Number)      (I.R.S. Employer
        of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ          08540
  ---------------------------------------------------------   --------------------
          (Address of Principal Executive Offices)                 (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 1.01    ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.
  
       On  April  21,   2006,   Cytogen   Corporation   ("Cytogen")   and  Savient
  Pharmaceuticals,  Inc.  ("Savient")  announced the  execution of a  distribution
  agreement   granting  Cytogen   exclusive   marketing  rights  for  SOLTAMOX(TM)
  (tamoxifen  citrate)  in the United  States.  SOLTAMOX,  a  cytostatic  estrogen
  receptor  antagonist,  is the first oral liquid hormonal therapy approved in the
  U.S.  It is  indicated  for the  treatment  of  breast  cancer in  adjuvant  and
  metastatic settings and to reduce the risk of breast cancer in women with ductal
  carcinoma in situ (DCIS) or with high risk of breast cancer.
  
       Under the terms of the final  transaction,  Cytogen paid Savient an upfront
  licensing  fee of $2  million  and will pay  additional  contingent  sales-based
  milestone  payments  of up to a total of $4 million  to  Savient  and its wholly
  owned  subsidiary,  Rosemont  Pharmaceuticals  Ltd  ("Rosemont").   Savient  and
  Rosemont will also receive royalties on net sales of SOLTAMOX
  
       Additionally, Cytogen has entered into a supply agreement with Rosemont for
  the  manufacture  and supply of  SOLTAMOX.  Cytogen  expects to launch  SOLTAMOX
  during the third quarter of 2006.
  
       Attached hereto and  incorporated by reference  herein as Exhibit 99.1 is a
  copy of the related press release of Cytogen and Savient,  dated April 24, 2006.
  A copy of the  Exclusive  Distribution  Agreement  and the  Manufacture & Supply
  Agreement will be filed as exhibits to Cytogen's  upcoming  quarterly  Report on
  Form 10-Q for the quarter ended March 31, 2006.
  
  ITEM 9.01    FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
        Exhibit No.      Description
        -----------      -----------
  
           99.1          Press Release of Cytogen and Savient dated April 24, 2006
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By:/s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   April 26, 2006
  EXHIBIT INDEX
  
        Exhibit No.      Description
        -----------      -----------
  
            99.1         Press Release of Cytogen and Savient dated April 24, 2006